Partner with the Centre for Drug Development

Smiling woman looking at someone sitting next to her.

We partner with academics, pharmaceutical, and biotech companies worldwide to develop novel cancer treatments which might not otherwise make it to clinical trial.

Leveraging world-class facilities and networks, we deliver preclinical evaluation, manufacturing and early-phase clinical trials.

Partners can access our expertise in antibodies, cell therapies, vaccines, drug conjugates and small molecules. Our flexible business models allow for shared risk-reward partnerships.

Get in touch

We are thrilled to be advancing KJ-103 into the clinic in partnership with Cancer Research UK. KJ-103 is the first of a new wave of antibodies to come from our modernised technology platform that leverages AI grounded in biology to create transformative antibody therapeutics.

— David Young, co-founder and CEO of KisoJi

Clinical development partnerships

Our drug development expertise enables us to design, sponsor and deliver science-driven, first in human clinical trials. We partner globally to increase the number of new cancer treatments, advancing novel oncology agents into clinical development to maximise impact for cancer patients.

Through these kinds of partnerships, we offer an alternative path for companies to fully realise their oncology pipelines and develop promising anti-cancer agents they might otherwise be unable to bring to clinical trial.

How do our clinical development partnerships work?

You grant us a licence to undertake a clinical trial while retaining background intellectual property rights.
We design, set up and deliver preclinical and early clinical development on a shared risk/reward basis through our Experimental Cancer Medicine Centres network.
You have the first option to license the clinical trial data, and partners can license results and intellectual property developed under the programme.

Discover our current portfolio

Email us to discuss partnering opportunities

Despite many breakthroughs in cancer research, some cancers are still very challenging to treat, and patients deserve better treatment options. We look forward to seeing how this trial progresses to investigate whether UCB4594 is a tolerated and effective treatment for potentially treating patients with advanced cancers.

— Professor Fiona Thistlethwaite, clinical trial lead for UCB4594

Academic sponsorship

We offer academic sponsorship through our Drug Development Project scheme. Applicants can access full preclinical and clinical development of promising anti-cancer agents originating from academic research.

Although our clinical trials are conducted in the UK, our academic partners are based around the world. If you are based outside of the UK and have a cutting-edge oncology therapeutic, contact us to find out more about how we can help you develop it.

All applications to the Drug Development Project are evaluated by our New Agents Committee.

Learn more about the scheme

Find out about our New Agents Committee